“Patents are often the main assets of small biotech companies, and they rely on this intellectual property to attract investors to fund the lengthy and expensive research and development process… The improvements made by the America Invents Act would benefit the biotechnology industry, and indeed all sectors of the U.S. economy, by enhancing patent quality and the efficiency, objectivity, predictability, and transparency of the patent system.”

Re: the first to invent vs. the first to file system they said:

“One of the most hotly debated provisions of the America Invents Act would change America’s first to invent system to a first inventor to file system. This system is embedded in international patent practice, with the United States as the only exception. While some argue that America’s first to invent system is superior, it is inherently fraught with uncertainties, and problems arise when biotechnology companies try to protect their inventions here and abroad. This bill would remove these uncertainties, while providing adequate protections against misappropriation of an invention by someone other than the true inventor”

They outline their opinions on other ways the new bill will affect the system as a whole. The blog is linked to the Biotechnology Industry Organization (BIO) who: “represent more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.”